The distribution of HLA-B27 subtype in patients with ankylosing spondylitis in Northern Norway

Abstract

HLA-B27*05 is the predominant subtype of HLA-B27 in Northern Norway. This supports the concept of a North-South gradient for HLA-B27 subtypes with little regional drive to adapt to environmental challenges. Low-resolution HLA-B27 PCR screening captures all relevant subtypes in this region.

Polymorphisms of human leukocyte antigen B*27 on clinical phenotype of spondyloarthritis in Chinese

“…8,9,16,18 Indeed, relatively few studies performed the profound and prudent exploration of its effects on disease expression or clinical severity of SpA patients. 37,39,41 In the current study, a noticeably male predominance and markedly elevated CRP were found in B*27 positive SpA patients. In multivariable linear regression analysis, the elevated CRP was significantly associated with HLA-B*27 positivity, grade of sacroiliitis, and male gender.…”

Tumor Necrosis Factor–α Promoter −308/238 Polymorphism Association with Less Severe Disease in Ankylosing Spondylitis is Unrelated to Serum TNF-α and Does Not Predict TNF Inhibitor Response

“…LD analysis (http://www.broadinstitute.org/mpg/snap/ ldsearch.php) using the Broad SNAP tool indicates an R2 of 0.009 and D¢ of 1.00, which makes it unlikely that LD was a significant confounder. Finally, while we failed to establish a link between TNF promoter polymorphism and HLA-B27, this only applies to this white cohort with an almost exclusive presence of the HLA-B27*05 subtype 42 .…”

HLA-B*27 in human health and disease

“…Moreover, the Venezuelan population presented the same pattern of association between Hla-B*2705 and Hla-B*2702 subtypes with as (7). There has been found no phenotypic difference regarding the clinical manifestations between the patients with Hla-B*2702 and those with Hla-B*2705 (25). On the other hand, Hla-B*2708 subtype has been found in the majority of healthy Venezuelan controls, and it was absent from the population with as, so this may suggest the association between Hla-B*2708 subtype and the protection against as (26).…”